Clinical Trials Logo

Recurrent Childhood Glioblastoma clinical trials

View clinical trials related to Recurrent Childhood Glioblastoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02444546 Completed - Glioma Clinical Trials

Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Start date: June 21, 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of wild-type reovirus (viral therapy) when given with sargramostim in treating younger patients with high grade brain tumors that have come back or that have not responded to standard therapy. A virus, called wild-type reovirus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells. Sargramostim may increase the production of blood cells and may promote the tumor cell killing effects of wild-type reovirus. Giving wild-type reovirus together with sargramostim may kill more tumor cells.

NCT ID: NCT00679354 Completed - Clinical trials for Recurrent Childhood Cerebellar Astrocytoma

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Start date: June 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor.

NCT ID: NCT00095940 Completed - Clinical trials for Recurrent Childhood Ependymoma

Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

Start date: October 2004
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.